tirzepatide age approval 🚨 Diabetes News Update for Families 🚨 Big update in pediatric diabetes care 👇 Mounjaro (tirzepatide) is now approved for children and adolescents ages 10 and older with type 2 diabetes. This Real-World Weight Loss Observed With

El tratamiento dual suele estar justificado si: Tienes un IMC muy elevado (Obesidad Grado II o III) y necesitas una reduccin de peso mayor al 15%

Durability of Results: Maintenance Studies: Tirzepatide (SURMOUNT-3): Continued treatment: Additional 5.5% weight loss Stopped treatment: Regained 14% of weight Conclusion: Need ongoing treatment Semaglutide (STEP-4): Continued treatment: Maintained loss, continued losing Stopped treatment: Regained most weight Conclusion: Need ongoing treatment Phentermine: FDA-approved for 12 weeks only Weight regain after stopping is universal Not a long-term solution All Weight Loss Medications: Obesity is chronic disease Medications treat symptoms, dont cure Stopping medication weight regain Long-term or indefinite use necessary for sustained results Safety Profile Comparison: Discontinuation Due to Side Effects: Tirzepatide: 6.2% Semaglutide: 6.9% Liraglutide: 9.9% Naltrexone-bupropion: 25% (very high) Orlistat: 15-20% Phentermine-topiramate: 8-10% GLP-1s have excellent tolerability considering their effectiveness

If your provider uses standard blood panels , creatinine-based eGFR may appear artificially low

Lab work, hormonal status, and relevant health history are all evaluated before a treatment protocol is recommended

Geographic Availability Not available in AL, AK, AR, HI, LA, MS, MO, SC, WV Clinical Oversight and Safety Prescribing is managed by licensed NPs or PAs under a physician-led team, including a DO chief medical officer and an MD endocrinologist